Literature DB >> 21169045

The uptake of influenza and pneumococcal vaccination among immunocompromised patients attending rheumatology outpatient clinics.

Muhammad Haroon1, Fahd Adeeb, Ahmed Eltahir, Sinead Harney.   

Abstract

PURPOSE AND
OBJECTIVES: The patients using immunosuppressive agents are considered at high risk for acquiring different infections. Accordingly, international guidelines recommend vaccinating such patients against influenza and pneumococcal organisms. The aims of this study were two-fold: (1) to assess the influenza and pneumococcal vaccination uptake among our rheumatology outpatients who are immunosuppressed; (2) to identify the factors influencing immunisation uptake among our sample of patients.
METHODS: This was a questionnaire-based study. Patients were eligible to partake in this study if they were using immunosuppressive drugs. During the study period (4 weeks), 337 patients were screened, and 110 patients fulfilled the criteria for inclusion.
RESULTS: Positive vaccination uptake of our cohort was as follows: common influenza alone (34%, 37 out of 110), pneumonia alone (11%, 12 out of 110), and both pneumococcal and influenza vaccination (11%). The status of influenza A (H1N1) vaccination was not recorded as a part of this audit. The two most common reasons cited by patients for non-uptake of vaccinations were: 'not offered' and 'thought it was unnecessary'. Of 37 patients who had influenza vaccination, 33 patients (89%) had additional risk factors, and there were only four patients who had influenza vaccine solely because they were taking immunosuppressive drugs. All pneumococcal vaccinated patients (n=12) were noted to have additional risk factors.
CONCLUSION: There is suboptimal uptake of influenza and pneumococcal vaccinations among immunosuppressed patients attending rheumatology outpatient clinics. These results are a cause of concern given the morbidity and mortality of associated infections.
Copyright © 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21169045     DOI: 10.1016/j.jbspin.2010.10.012

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  13 in total

1.  A Multifaceted Intervention to Improve Influenza, Pneumococcal, and Herpes Zoster Vaccination among Patients with Rheumatoid Arthritis.

Authors:  David W Baker; Tiffany Brown; Ji Young Lee; Amanda Ozanich; David T Liss; Diana S Sandler; Eric M Ruderman
Journal:  J Rheumatol       Date:  2016-04-15       Impact factor: 4.666

Review 2.  Understanding factors associated with vaccine uptake and vaccine hesitancy in patients with rheumatoid arthritis: a scoping literature review.

Authors:  Vincent Gosselin Boucher; Sandra Pelaez; Claudia Gemme; Sara Labbe; Kim L Lavoie
Journal:  Clin Rheumatol       Date:  2020-07-03       Impact factor: 2.980

3.  Immunology: Prevention of infections in patients with autoimmune diseases.

Authors:  Dirk Meyer-Olson; Torsten Witte
Journal:  Nat Rev Rheumatol       Date:  2011-02-08       Impact factor: 20.543

Review 4.  Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective.

Authors:  Charles R Beck; Bruce C McKenzie; Ahmed B Hashim; Rebecca C Harris; Arina Zanuzdana; Gabriel Agboado; Elizabeth Orton; Laura Béchard-Evans; Gemma Morgan; Charlotte Stevenson; Rachel Weston; Mitsuru Mukaigawara; Joanne Enstone; Glenda Augustine; Mobasher Butt; Sophie Kim; Richard Puleston; Girija Dabke; Robert Howard; Julie O'Boyle; Mary O'Brien; Lauren Ahyow; Helene Denness; Siobhan Farmer; Jose Figureroa; Paul Fisher; Felix Greaves; Munib Haroon; Sophie Haroon; Caroline Hird; Rachel Isba; David A Ishola; Marko Kerac; Vivienne Parish; Jonathan Roberts; Julia Rosser; Sarah Theaker; Dean Wallace; Neil Wigglesworth; Liz Lingard; Yana Vinogradova; Hiroshi Horiuchi; Javier Peñalver; Jonathan S Nguyen-Van-Tam
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

5.  Predictors of Influenza Vaccination in Early Rheumatoid Arthritis 2017-2021: Results From the Canadian Early Arthritis Cohort.

Authors:  Viviane Ta; Orit Schieir; Marie-France Valois; Ines Colmegna; Carol Hitchon; Louis Bessette; Glen Hazlewood; Carter Thorne; Janet Pope; Gilles Boire; Diane Tin; Edward C Keystone; Vivian P Bykerk; Susan J Bartlett
Journal:  ACR Open Rheumatol       Date:  2022-03-29

6.  A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK.

Authors:  Sujith Subesinghe; Andrew Ian Rutherford; Fowzia Ibrahim; Helen Harris; James Galloway
Journal:  BMC Musculoskelet Disord       Date:  2016-08-04       Impact factor: 2.362

Review 7.  Barriers of Influenza Vaccination Intention and Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005 - 2016.

Authors:  Philipp Schmid; Dorothee Rauber; Cornelia Betsch; Gianni Lidolt; Marie-Luisa Denker
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

8.  Low Influenza, Pneumococcal and Diphtheria-Tetanus-Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren's Syndrome: A Cross-Sectional Study.

Authors:  Jacques Morel; Hind Letaief; Philippe Guilpain; Xavier Mariette; Bernard Combe; Cédric Lukas
Journal:  Vaccines (Basel)       Date:  2019-12-21

9.  Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink.

Authors:  Ruth Costello; Kevin L Winthrop; Stephen R Pye; Benjamin Brown; William G Dixon
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

10.  Predictors and temporal trend of flu vaccination in auto-immune rheumatic diseases in the UK: a nationwide prospective cohort study.

Authors:  Georgina Nakafero; Matthew J Grainge; Puja R Myles; Christian D Mallen; Weiya Zhang; Michael Doherty; Jonathan S Nguyen-Van-Tam; Abhishek Abhishek
Journal:  Rheumatology (Oxford)       Date:  2018-10-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.